CO2018014085A2 - Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave - Google Patents
Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suaveInfo
- Publication number
- CO2018014085A2 CO2018014085A2 CONC2018/0014085A CO2018014085A CO2018014085A2 CO 2018014085 A2 CO2018014085 A2 CO 2018014085A2 CO 2018014085 A CO2018014085 A CO 2018014085A CO 2018014085 A2 CO2018014085 A2 CO 2018014085A2
- Authority
- CO
- Colombia
- Prior art keywords
- beta
- soft gel
- hydroxyisovaleric acid
- stabilization
- gel capsules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
RESUMEN Las divulgaciones son composiciones estables al almacenamiento, de gel blando y que contienen ácido beta-hidroxiisovalérico, y métodos para preparar tales composiciones. En ciertos aspectos, las composiciones descritas comprenden una cubierta de cápsula a base de plantas y una formulación líquida que comprende ácido beta-hidroxiisovalérico y al menos un excipiente, en la que la cápsula de gel blando es estable en almacenamiento. En ciertos aspectos, el excipiente se selecciona de entre sal de colina, betaína, fosfatidilcolina, alfa-glicerofosfocolina, carnitina, adenosina 5'-trifosfato, o una combinación de las mismas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341464P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034551 WO2017205673A1 (en) | 2016-05-25 | 2017-05-25 | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018014085A2 true CO2018014085A2 (es) | 2019-03-18 |
Family
ID=60411620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0014085A CO2018014085A2 (es) | 2016-05-25 | 2018-12-24 | Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10959957B2 (es) |
| EP (1) | EP3463327B1 (es) |
| JP (1) | JP6929939B2 (es) |
| KR (1) | KR102384266B1 (es) |
| CN (1) | CN109562087A (es) |
| AU (1) | AU2017270219B2 (es) |
| BR (1) | BR112018073949A8 (es) |
| CA (1) | CA3024584A1 (es) |
| CO (1) | CO2018014085A2 (es) |
| MX (1) | MX2018014407A (es) |
| MY (1) | MY199597A (es) |
| RU (1) | RU2018145520A (es) |
| WO (1) | WO2017205673A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111888325A (zh) * | 2020-08-04 | 2020-11-06 | 瑞希(重庆)生物科技有限公司 | 一种卡拉胶凝胶、药物赋形剂和皮肤外用制剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) * | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| US5200191A (en) | 1991-09-11 | 1993-04-06 | Banner Gelatin Products Corp. | Softgel manufacturing process |
| US5569466A (en) | 1995-05-17 | 1996-10-29 | R. P. Scherer Corporation | Fill compositions for soft elastic gel capsules |
| US6340473B1 (en) * | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| DE10064312C2 (de) | 2000-12-22 | 2003-05-22 | Degussa | Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung |
| US7740878B2 (en) * | 2001-10-22 | 2010-06-22 | Danisco A/S | Use of betaine to enhance exercise performance |
| DE60222803T2 (de) | 2001-12-21 | 2008-07-17 | Supernus Pharmaceuticals, Inc. | Orale kapselformulierung mit verbesserter physikalischer stabilität |
| DE10208568A1 (de) | 2002-02-27 | 2003-09-18 | Degussa Bioactives Deutschland | Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner |
| DE10217557A1 (de) | 2002-04-19 | 2003-11-06 | Degussa Bioactives Gmbh | Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix |
| US8231896B2 (en) * | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
| DE102004060914A1 (de) | 2004-12-17 | 2006-07-06 | Bioghurt Biogarde Gmbh & Co. Kg | Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen |
| EP2242489A1 (en) | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
| DE102005061765A1 (de) | 2005-05-19 | 2006-11-23 | Degussa FreshTech Beverages LLC, Milwaukee | Füllmaterial für einen Getränkebehälter |
| CN101574146B (zh) * | 2008-05-07 | 2012-06-13 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动营养补剂 |
| JP2009153529A (ja) | 2009-04-17 | 2009-07-16 | Tsujido Chemical Corp | 食品組成物 |
| HUE032486T2 (en) * | 2009-12-18 | 2018-05-02 | Metabolic Tech Inc | An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB) |
| BR112013016187A2 (pt) | 2010-12-22 | 2018-07-10 | Abbott Lab | Produtos nutricionais compreendendo beta- hidróxi-beta metilbutirato de cálcio e ácido linoléico conjungado. |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| WO2014040067A1 (en) * | 2012-09-10 | 2014-03-13 | Metabolic Technologies, Inc. | Composition of hmb and atp and methods of use |
| US20140272000A1 (en) | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
| JP6389237B2 (ja) * | 2013-03-15 | 2018-09-12 | パセオン ソフトジェルズ インコーポレイティド | 非ゼラチン性腸溶性軟質カプセル |
| WO2015094925A1 (en) * | 2013-12-18 | 2015-06-25 | Capsugel Belgium Nv | Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid |
| US20150366813A1 (en) * | 2014-06-20 | 2015-12-24 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
| JP2018090504A (ja) * | 2016-11-30 | 2018-06-14 | 株式会社東洋新薬 | 筋肉増強用組成物 |
-
2017
- 2017-05-25 RU RU2018145520A patent/RU2018145520A/ru not_active Application Discontinuation
- 2017-05-25 EP EP17803618.2A patent/EP3463327B1/en active Active
- 2017-05-25 AU AU2017270219A patent/AU2017270219B2/en active Active
- 2017-05-25 CN CN201780031975.2A patent/CN109562087A/zh active Pending
- 2017-05-25 CA CA3024584A patent/CA3024584A1/en active Pending
- 2017-05-25 MX MX2018014407A patent/MX2018014407A/es unknown
- 2017-05-25 JP JP2019514190A patent/JP6929939B2/ja active Active
- 2017-05-25 BR BR112018073949A patent/BR112018073949A8/pt active Search and Examination
- 2017-05-25 WO PCT/US2017/034551 patent/WO2017205673A1/en unknown
- 2017-05-25 KR KR1020187037387A patent/KR102384266B1/ko active IP Right Grant
- 2017-05-25 MY MYPI2018002008A patent/MY199597A/en unknown
- 2017-05-25 US US15/605,664 patent/US10959957B2/en active Active
-
2018
- 2018-12-24 CO CONC2018/0014085A patent/CO2018014085A2/es unknown
-
2021
- 2021-03-30 US US17/217,913 patent/US20210212953A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3463327A4 (en) | 2020-01-22 |
| BR112018073949A2 (pt) | 2019-02-26 |
| CA3024584A1 (en) | 2017-11-30 |
| MY199597A (en) | 2023-11-08 |
| CN109562087A (zh) | 2019-04-02 |
| JP2019517576A (ja) | 2019-06-24 |
| RU2018145520A (ru) | 2020-06-25 |
| US10959957B2 (en) | 2021-03-30 |
| WO2017205673A1 (en) | 2017-11-30 |
| US20210212953A1 (en) | 2021-07-15 |
| MX2018014407A (es) | 2019-02-21 |
| AU2017270219B2 (en) | 2023-03-16 |
| KR20190021259A (ko) | 2019-03-05 |
| KR102384266B1 (ko) | 2022-04-06 |
| EP3463327A1 (en) | 2019-04-10 |
| RU2018145520A3 (es) | 2020-08-26 |
| US20170340572A1 (en) | 2017-11-30 |
| EP3463327B1 (en) | 2024-04-17 |
| BR112018073949A8 (pt) | 2023-03-21 |
| JP6929939B2 (ja) | 2021-09-01 |
| AU2017270219A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021005774A2 (es) | Lípidos con amina ionizables | |
| CL2019000586A1 (es) | Composiciones de toxinas clostridiales no proteicas. | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| CO2017012893A2 (es) | Composiciones farmacéuticas que comprenden péptidos neo-antígenos o una sal de los mismos y métodos para preparar las mismas | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
| BR112018003031A2 (pt) | formulações clínicas | |
| CL2021000217A1 (es) | Composiciones de péptidos tau fosforilados y sus usos. (divisional de solicitud 1070-2020) | |
| UY37818A (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| CL2016002607A1 (es) | Procedimiento para preparar una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de obtener una solución acuosa de acetato de glatiramer y manitol, filtración de la solución entre 0 y 17,5 grado celsius y llenado del contenedor. pct | |
| AR100519A1 (es) | Envase tipo cápsula de gelatina blanda y su método de fabricación | |
| AR105237A1 (es) | Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
| PE20120422A1 (es) | Formulaciones orales solidas de (r)-2-amino-7-[4-fluoro-2-(6-metoxi-piridin-2-il)-fenil]-4-metil-7,8-dihidro-6h-pirido-[4,3-d]-pirimidin-5-ona | |
| CO2018014085A2 (es) | Estabilización de formulaciones de ácido beta-hidroxiisovalérico en cápsulas de gel suave | |
| PE20180928A1 (es) | Sales y profarmacos de 1-metil-d-triptofano | |
| CL2015002324A1 (es) | Método para el tratamiento y control de enfermedades de postrecolección de frutas y hortalizas y composiciones que comprenden extractos naturales y formulaciones fitofortificantes y/o fungicidas para aplicar en dicho método. | |
| CL2018001151A1 (es) | Suspensión acuosa para administración oral y método para su preparación | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX2019005160A (es) | Formulacion farmaceutica. | |
| CO2020016008A2 (es) | Formulación de proteína de fusión estable | |
| CL2019003801A1 (es) | Nuevas formulaciones orales de belinostato. | |
| UY38043A (es) | Combinación farmacéutica que comprende tramadol clorhidrato de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor | |
| CL2018001797A1 (es) | Formulación galénica que comprende un fármaco tópico |